2024-2025 Guide for Malaysian Cancer Patients Travelling to China: A Full Analysis of the Approval and Availability of New Drugs for EGFR Exon 20 Insertion Mutations in China
A detailed breakdown of sunvozertinib (Sunvozertinib®) and mobocertinib in terms of real-world clinical efficacy in China, the closed-loop prescribing pathway for Malaysian patients travelling to China, and a transparent comparison of commercial medical insurance and policy admission.
For EGFR exon 20 insertion mutations (Exon 20ins), China's domestically developed next-generation highly selective inhibitor sunvozertinib (Sunvozertinib®) has lifted the second-line objective response rate (cORR) from 15% with conventional chemotherapy to 50.8%, and achieves potent intracranial control of nearly 50% in brain metastases. Malaysian patients can use the 30-day mutual visa exemption or an S2 medical visa and, through YILV CHINA's standardised green channel, reach Shanghai Chest Hospital or Peking Union Medical College Hospital in as little as 72 hours to complete authorised prescribing and genetic re-verification.
1. The Clinical Dilemma and Information Gap for Malaysian Patients: Why Is Exon 20ins Called a "Targeting Desert"?
Among Chinese and other Asian patients with non-small cell lung cancer (NSCLC) in Malaysia, EGFR mutations occur in as many as 45%–55% of cases. Yet most patients and families are familiar with the classic sensitising mutations (such as exon 19 deletion Del19 and exon 21 L858R), for which both the private and public Malaysian healthcare systems have ample first- to third-generation targeted drugs (gefitinib, osimertinib and others).
By contrast, EGFR exon 20 insertion mutations (EGFR Exon 20ins) account for about 4%–10% of all EGFR mutations and are described as a refractory "mutation black hole". Because of their unusual protein steric conformation, conventional first-, second- and third-generation EGFR-TKIs bind them very weakly and show innate primary resistance.
No highly selective oral targeted drug in later lines
- •Resistance to conventional TKIs is close to 100%, and blind dose escalation of osimertinib rarely delivers sustained clinical benefit.
- •Standard care relies mainly on pemetrexed plus platinum intravenous chemotherapy, with a median progression-free survival (mPFS) of only 4.2–5.5 months.
- •After mobocertinib was withdrawn globally or its supply restricted, second-line targeted options in Malaysia became extremely scarce.
The world's first full-spectrum targeted breakthrough
- •Sunvozertinib® (sunvozertinib) has received conditional full marketing approval from China's National Medical Products Administration (NMPA), and prescribing supply is stable.
- •In previously treated Exon 20ins mutations, the objective response rate (ORR) reaches 50.8% and the disease control rate reaches 89.0%.
- •Amivantamab (a bispecific antibody) has likewise established a standard combination dosing pathway at leading centres in China.
Quantified comparison of key efficacy data: conventional chemotherapy vs sunvozertinib (Sunvozertinib)
2. Molecular Mechanism of the Drug and a Detailed Review of the WU-KONG6 Registrational Clinical Evidence
Sunvozertinib (development code DZD9008) has caused a stir in the global oncology community because of its specially designed flexible molecular structure, created to overcome the conformational constraints of exon 20 insertion mutations. When conventional inhibitors bind to the mutant site, they are highly prone to steric collision or to non-specific inhibition of wild-type EGFR (causing severe rash and diarrhoea that make an effective targeted dose impossible to maintain).
Highly selective binding: bypassing the wild-type toxicity window
Through a precisely engineered pharmacophore configuration, sunvozertinib reaches deep into the allosterically formed binding pocket. Against more than 30 different Exon 20ins mutant subtypes (including near-loop and far-loop insertions) it shows potent and uniform nanomolar inhibitory activity, with a selective inhibition window over wild-type EGFR of more than 5-fold.
In-depth analysis of clinical data from the pivotal phase II WU-KONG6 (Wukong 6) trial
The WU-KONG6 study, published in the leading international medical journal The Lancet Respiratory Medicine, enrolled 97 patients with advanced non-small cell lung cancer harbouring EGFR Exon 20ins who had progressed after platinum-based chemotherapy:
Potent intracranial control in patients with brain metastases
In the subgroup with stable central nervous system (CNS) brain metastases at baseline, the intracranial ORR assessed by the independent review committee (IRC) reached nearly 50.0%. The drug crosses the blood-brain barrier, substantially delaying cerebral oedema and intracranial deterioration in advanced lung cancer.
Safety and stepwise management of adverse events
The most common adverse reactions are diarrhoea (mostly grade 1–2) and rash. Only a very small proportion of patients in clinical trials (about 6%) discontinued treatment because of adverse reactions. The YILV CHINA clinical team provides pre-emptive anti-diarrhoeal guidance (a standardised stepwise loperamide regimen) and a bilingual contingency plan drawn up with the Chinese attending director.
3. The Closed-Loop Care Pathway for Malaysian Patients in China and the Compliant "Three Payment Streams" Billing
The greatest pain points in cross-border care are policy compliance, restrictions on carrying personal medication across borders, and financial opacity. YILV CHINA applies strict transparent billing standards: all medical fees are settled directly by the patient into the hospital's public account, with no intermediary mark-up.
Malaysian slides and initial NGS review
Our Kuala Lumpur centre re-verifies the Malaysian reports and confirms the matching Grade 3A target indication within 24 hours.
Specialist consultation with authorised Grade 3A experts
We secure a specialist director at Shanghai Chest Hospital, Fudan University Shanghai Cancer Center or Sun Yat-sen University Cancer Center, with rapid green-channel registration.
Medication in China and discharge prescription
With 30-day visa-free entry or an S2 medical visa, a compliant personal-medication prescription is issued after baseline re-examination.
Malaysian policy claims and follow-up
A full bilingual medical record set with corporate receipts to support AIA / Great Eastern claim settlement.
Detailed cost transparency comparison (reference exchange rate: $1 MYR ≈ 1.63 CNY)
| Cost category | Comparable drugs elsewhere overseas / private | Official self-pay at Chinese public Grade 3A hospitals | Malaysian policy claim support |
|---|---|---|---|
| Monthly cost of the new targeted drug | Approx. RM 25,000 – RM 35,000 | Approx. RM 9,200 – RM 11,500(saving about 65%–70%) | Official invoices and prescription evidence issued to support overseas claims |
| Specialist premium consultation and assessment | RM 1,200 – RM 2,000 | CNY 300 – 1,000 (approx. RM 180 – RM 600) | Official Grade 3A outpatient registration receipt |
| YILV CHINA cross-border coordination | Typical agencies take 15%–30% of the drug cost | $300 USD (record restructuring, specialist review and hospital coordination included, no hidden mark-up) | Includes medical record translation, green-channel registration and hospital coordination |
Note: all drug and examination fees at Chinese Grade 3A hospitals are paid directly by the patient or family member at the hospital cashier window or through the hospital's official WeChat / Alipay public account.
4. A Real Malaysian Patient Case: A 52-Year-Old Woman in Penang Reverses Drug Resistance
Madam Tan (52 years old)Penang, Malaysia · Retired teacherThird-generation targeted therapy resistance: authorised prescribing started at Shanghai Chest Hospital
History: diagnosed with advanced lung adenocarcinoma at a private hospital in Penang in 2023. After blind osimertinib treatment and second-line pemetrexed plus carboplatin chemotherapy, the primary lesion continued to enlarge, with multiple micronodules spreading through both lungs. Tissue was re-collected for NGS genomic re-testing in Malaysia, confirming a very rare EGFR Exon 20 insertion mutation (S768_D770dup).
Referral timeline to China: the original NGS report was submitted through the YILV CHINA Kuala Lumpur office on a Monday; remote preliminary review by a respiratory oncology specialist at Shanghai Chest Hospital confirmed eligibility on the Wednesday; she flew directly to Shanghai on 30-day visa-free entry on the Friday; blood tests and the targeted therapy assessment were completed on the Saturday, and oral sunvozertinib 300mg QD was started immediately.